NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Dracen Pharmaceuticals, Inc.

Dracen Pharmaceuticals, Inc.

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://www.dracenpharma.com/

Last Round

Debt

Jul 27, 2023

Total Funding Raised

$61.8M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Dracen Pharmaceuticals, Inc. is a biotechnology company that develops cancer treatment medicines intended to shrink tumors and remodel the tumor microenvironment.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immuno-metabolismoncologyglutamine antagonistcancer metabolismimmuno-oncologyprodrugclinical-stage biotechcancer therapysolid tumorstumor microenvironmentnon-small cell lung cancerNSCLCFLCfibrolamellar carcinomacheckpoint inhibitorsdrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Dracen Pharmaceuticals, Inc. Comparables

Compare Dracen Pharmaceuticals, Inc. with similar companies based on industry and business-model similarity.

Dracen Pharmaceuticals, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ImmunoMet Therapeutics
81%
Cornerstone Pharmaceuticals, Inc.
77%
Rafael Holdings, Inc.
76%

Dracen Pharmaceuticals, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtJul 27, 2023
Series A ExtensionMar 10, 2022
Series A ExtensionNov 1, 2021
Series AMar 22, 2018

Dracen Pharmaceuticals, Inc. Investors

Notable investors and investment history

Dracen Pharmaceuticals, Inc. investors
InvestorRounds
Deerfield ManagementSeries A
Osage University PartnersSeries A
i&i PragueSeries A, Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2026

    Monthly visitors increased 116% MoM, reaching 2K.

  • Mar 22, 2018

    $41M round led by Deerfield Management.

Dracen Pharmaceuticals, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Dracen Pharmaceuticals, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Dracen Pharmaceuticals, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range4
Year Founded2016
Last FundingJul 27, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.